Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04308681
Registration number
NCT04308681
Ethics application status
Date submitted
12/03/2020
Date registered
16/03/2020
Date last updated
24/10/2023
Titles & IDs
Public title
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Query!
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
Query!
Secondary ID [1]
0
0
2019-003992-21
Query!
Secondary ID [2]
0
0
IM027-040
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - BMS-986278 Placebo
Treatment: Drugs - BMS-986278
Experimental: IPF Dose 1 + Post Treatment Follow-up or OTE - IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
Experimental: IPF Dose 2 + Post Treatment Follow-up or OTE -
Placebo comparator: IPF Placebo + Post Treatment Follow-up or OTE -
Experimental: PF-ILD Dose 1 + Post Treatment Follow-up or OTE - PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
Experimental: PF-ILD Dose 2 + Post Treatment Follow-up or OTE -
Placebo comparator: PF-ILD Placebo + Post Treatment Follow-up or OTE -
Other interventions: BMS-986278 Placebo
Specified Dose on Specified Days
Treatment: Drugs: BMS-986278
Specified Dose on Specified Days
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Rate of change in percent predicted forced vital capacity(ppFVC) in Idiopathic Pulmonary Fibrosis (IPF) Participants
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to week 26
Query!
Secondary outcome [1]
0
0
Incidence of Adverse Events (AEs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 26 weeks
Query!
Secondary outcome [2]
0
0
Incidence of Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 26 weeks
Query!
Secondary outcome [3]
0
0
Incidence of Adverse Events (AEs) leading to early discontinuation of study treatment
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 26 weeks
Query!
Secondary outcome [4]
0
0
Incidence of Treatment-Emergent Deaths
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to 26 weeks
Query!
Secondary outcome [5]
0
0
Incidence of clinically significant changes in clinical laboratory results: Hematology tests
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to 26 weeks
Query!
Secondary outcome [6]
0
0
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to 26 weeks
Query!
Secondary outcome [7]
0
0
Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to 26 weeks
Query!
Secondary outcome [8]
0
0
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval
Query!
Assessment method [8]
0
0
PR interval: The time from the onset of the P wave to the start of the QRS complex
Query!
Timepoint [8]
0
0
Up to 26 weeks
Query!
Secondary outcome [9]
0
0
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval
Query!
Assessment method [9]
0
0
QRS interval: A combination of the Q wave, R wave and S wave, the "QRS complex" represents ventricular depolarization
Query!
Timepoint [9]
0
0
Up to 26 weeks
Query!
Secondary outcome [10]
0
0
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval
Query!
Assessment method [10]
0
0
QT interval: Measured from the beginning of the QRS complex to the end of the T wave
Query!
Timepoint [10]
0
0
Up to 26 weeks
Query!
Secondary outcome [11]
0
0
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF interval
Query!
Assessment method [11]
0
0
QTcF interval: Corrected QT interval using Fridericia's formula (QTcF)
Query!
Timepoint [11]
0
0
Up to 26 weeks
Query!
Secondary outcome [12]
0
0
Incidence of clinically significant changes in vital signs: Body temperature
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to 26 weeks
Query!
Secondary outcome [13]
0
0
Incidence of clinically significant changes in vital signs: Respiratory rate
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Up to 26 weeks
Query!
Secondary outcome [14]
0
0
Incidence of clinically significant changes in vital signs: Blood pressure
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Up to 26 weeks
Query!
Secondary outcome [15]
0
0
Incidence of clinically significant changes in vital signs: Heart rate
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Up to 26 weeks
Query!
Secondary outcome [16]
0
0
Incidence of clinically significant changes in physical examination findings
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Up to 26 weeks
Query!
Secondary outcome [17]
0
0
Rate of change in ppFVC in progressive fibrotic interstitial lung disease (PF-ILD) participants
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
Up to 26 weeks
Query!
Secondary outcome [18]
0
0
Proportion of participants with = 10% absolute decline in ppFVC (%)
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
At weeks 4, 8, 12, 16, 20, and 26
Query!
Secondary outcome [19]
0
0
Proportion of participants with > 0% change in ppFVC
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
At weeks 4, 8, 12, 16, 20, and 26
Query!
Secondary outcome [20]
0
0
Time to first acute exacerbation
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
Up to 26 weeks
Query!
Secondary outcome [21]
0
0
Time to first = 10% absolute decline in ppFVC (%)
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
Up to 26 weeks
Query!
Secondary outcome [22]
0
0
Absolute change in FVC (mL) from baseline to Week 26
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
Up to 26 weeks
Query!
Secondary outcome [23]
0
0
Absolute change in ppFVC (%) from baseline to Week 26
Query!
Assessment method [23]
0
0
Query!
Timepoint [23]
0
0
Up to 26 weeks
Query!
Secondary outcome [24]
0
0
Absolute change in single-breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26
Query!
Assessment method [24]
0
0
Query!
Timepoint [24]
0
0
Up to 26 weeks
Query!
Secondary outcome [25]
0
0
Absolute change in ppDLCO SB (%) (corrected for hemoglobin) from baseline to Week 26
Query!
Assessment method [25]
0
0
Query!
Timepoint [25]
0
0
Up to 26 weeks
Query!
Secondary outcome [26]
0
0
Change in walking endurance/distance from baseline at Week 26 as measured using the 6-Minute Walk Test (6MWT)
Query!
Assessment method [26]
0
0
Query!
Timepoint [26]
0
0
Up to 26 weeks
Query!
Secondary outcome [27]
0
0
Proportion of participants with acute exacerbations of lung fibrosis
Query!
Assessment method [27]
0
0
Query!
Timepoint [27]
0
0
Up to 26 weeks
Query!
Secondary outcome [28]
0
0
Maximum observed concentration (Cmax) of BMS-986278
Query!
Assessment method [28]
0
0
Query!
Timepoint [28]
0
0
Day 1 and Week 4
Query!
Secondary outcome [29]
0
0
Time of maximum observed concentration (Tmax) of BMS-986278
Query!
Assessment method [29]
0
0
Query!
Timepoint [29]
0
0
Day 1 and Week 4
Query!
Secondary outcome [30]
0
0
Area under the plasma concentration-time curve form time 0 to 8 hours post dose of BMS-986278 (AUC(0-8))
Query!
Assessment method [30]
0
0
Query!
Timepoint [30]
0
0
Day 1 and Week 4
Query!
Secondary outcome [31]
0
0
Trough observed plasma concentration (Ctrough) of BMS-986278
Query!
Assessment method [31]
0
0
Query!
Timepoint [31]
0
0
Week 4 and Week 12
Query!
Eligibility
Key inclusion criteria
For the idiopathic pulmonary fibrosis (IPF) Cohort
* Diagnosis of IPF within 7 years of screening
* Female and males = 40 years of age
For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
* Evidence of progressive ILD within the 24 months before screening
* Female and male = 21 years of age.
Query!
Minimum age
21
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Women of childbearing potential (WOCBP)
* Active Smokers
* Current malignancy or previous malignancy up to 5 years prior to screening
* History of allergy to BMS-986278 or related compounds
Other protocol-defined inclusion/exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/07/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/09/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
399
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - 0045 - Camperdown
Query!
Recruitment hospital [2]
0
0
Local Institution - 0025 - Westmead
Query!
Recruitment hospital [3]
0
0
Local Institution - 0026 - Brisbane
Query!
Recruitment hospital [4]
0
0
Local Institution - 0046 - Greenslopes
Query!
Recruitment hospital [5]
0
0
Local Institution - 0022 - Adelaide
Query!
Recruitment hospital [6]
0
0
Local Institution - 0023 - Heidelberg
Query!
Recruitment hospital [7]
0
0
Local Institution - 0021 - Murdoch
Query!
Recruitment hospital [8]
0
0
Local Institution - 0044 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4032 - Brisbane
Query!
Recruitment postcode(s) [4]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [5]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [7]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [8]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Distrito Federal
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Santa FE
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Tucuman
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos AIres
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Buenos Aires
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Mendoza
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Brussels
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Leuven
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Liège
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
RIO Grande DO SUL
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
SAO Paulo
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Sao Paulo
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
Chile
Query!
State/province [31]
0
0
Maule
Query!
Country [32]
0
0
Chile
Query!
State/province [32]
0
0
Valparaiso
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Beijing
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Hubei
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Shanghai
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Bobigny
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Bron
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Dijon
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Marseille
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Paris
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Rennes
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Toulouse
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Niedersachsen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Essen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Freiburg
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Grosshansdorf
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Heidelberg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Munich
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Stuttgart
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Haifa
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Jerusalem
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Petah Tikva
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Ramat Gan
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Tel Aviv
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Catania
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Modena
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Monza
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Roma
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Aichi
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Fukushima
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Hokkaido
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Hyogo
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Kanagawa
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Osaka
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Shimane
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Shizuoka
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Tokyo
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Kumamoto
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Nagasaki
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Saitama
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Seoul
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Distrito Federal
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Nuevo Leon
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Nuevo LEON
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Oaxaca
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Barcelona
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
L'Hospitalet de Llobregat
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Madrid
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Marbella Málaga
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Pozuelo de Alarcon
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Santander
Query!
Country [82]
0
0
Taiwan
Query!
State/province [82]
0
0
Kaohsiung
Query!
Country [83]
0
0
Taiwan
Query!
State/province [83]
0
0
Taipei
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Cambridge
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Edinburgh
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04308681
Query!
Trial related presentations / publications
Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026. doi: 10.1136/bmjresp-2021-001026. Cheng PTW, Kaltenbach RF 3rd, Zhang H, Shi J, Tao S, Li J, Kennedy LJ, Walker SJ, Shi Y, Wang Y, Dhanusu S, Reddigunta R, Kumaravel S, Jusuf S, Smith D, Krishnananthan S, Li J, Wang T, Heiry R, Sum CS, Kalinowski SS, Hung CP, Chu CH, Azzara AV, Ziegler M, Burns L, Zinker BA, Boehm S, Taylor J, Sapuppo J, Mosure K, Everlof G, Guarino V, Zhang L, Yang Y, Ruan Q, Xu C, Apedo A, Traeger SC, Cvijic ME, Lentz KA, Tirucherai G, Sivaraman L, Robl J, Ellsworth BA, Rosen G, Gordon DA, Soars MG, Gill M, Murphy BJ. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. J Med Chem. 2021 Nov 11;64(21):15549-15581. doi: 10.1021/acs.jmedchem.1c01256. Epub 2021 Oct 28.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04308681
Download to PDF